{"filing":{"accession_number":"0001213900-26-071082","cik":"0001711754","ticker":"INMB","company_name":"Inmune Bio, Inc.","form":"8-K","filing_date":"2026-06-23","report_date":null,"primary_document":"ea0295635-8k_inmune.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026071082/ea0295635-8k_inmune.htm"},"events":[{"id":13149,"run_id":11669,"accession_number":"0001213900-26-071082","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"INmune Bio announced receipt of official MHRA written alignment from a pre-MAA Scientific Advice meeting for CORDStrom™ (Ebstrocel™) in RDEB, confirming agreement on CMC, non-clinical, and clinical evidence packages and providing a \"clear regulatory path\" for a planned 2026 UK Marketing Authorization Application. This is a material regulatory milestone de-risking the development program and advancing the company toward a key commercialization objective, but it is not a completed M\u0026A transaction, earnings release, executive change, or other specifically-named event type—it is a significant operational/regulatory milestone in the drug development lifecycle.","company_name":"Inmune Bio, Inc.","ticker":"INMB","filing_date":"2026-06-23","form":"8-K","submitted_at":null,"items":[{"id":10214,"accession_number":"0001213900-26-071082","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"INmune Bio announced receipt of official MHRA written alignment from a pre-MAA Scientific Advice meeting for CORDStrom™ (Ebstrocel™) in RDEB, confirming agreement on CMC, non-clinical, and clinical evidence packages and providing a \"clear regulatory path\" for a planned 2026 UK Marketing Authorization Application. This is a material regulatory milestone de-risking the development program and advancing the company toward a key commercialization objective, but it is not a completed M\u0026A transaction, earnings release, executive change, or other specifically-named event type—it is a significant operational/regulatory milestone in the drug development lifecycle.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T20:07:23.430056+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10214,"accession_number":"0001213900-26-071082","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"INmune Bio announced receipt of official MHRA written alignment from a pre-MAA Scientific Advice meeting for CORDStrom™ (Ebstrocel™) in RDEB, confirming agreement on CMC, non-clinical, and clinical evidence packages and providing a \"clear regulatory path\" for a planned 2026 UK Marketing Authorization Application. This is a material regulatory milestone de-risking the development program and advancing the company toward a key commercialization objective, but it is not a completed M\u0026A transaction, earnings release, executive change, or other specifically-named event type—it is a significant operational/regulatory milestone in the drug development lifecycle.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T20:07:23.430056+00:00","company_name":"Inmune Bio, Inc.","ticker":"INMB","filing_date":"2026-06-23"}]}